Sickle Cell Disease and the Kidney: Pathophysiology and Novel Biomarkers.

4区 医学 Q3 Medicine Contributions to nephrology Pub Date : 2021-01-01 Epub Date: 2021-08-03 DOI:10.1159/000517703
Romélia Pinheiro Gonçalves Lemes, Marilia Rocha Laurentino, Luan Rebouças Castelo, Geraldo Silva Junior
{"title":"Sickle Cell Disease and the Kidney: Pathophysiology and Novel Biomarkers.","authors":"Romélia Pinheiro Gonçalves Lemes,&nbsp;Marilia Rocha Laurentino,&nbsp;Luan Rebouças Castelo,&nbsp;Geraldo Silva Junior","doi":"10.1159/000517703","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical Background: Renal involvement in sickle cell disease (SCD), called sickle cell nephropathy (SCN), includes several renal manifestations, such as renal acidification defect, distal nephron dysfunction, renal papillary necrosis, and proteinuria related to glomerular injury, leading to end-stage renal disease. Epidemiology: Many patients with SCD have a defect in urinary concentration, a problem caused by the destruction of the renal medulla that initiates in childhood. The presence of proteinuria in SCD is age-related and starts as microalbuminuria in adolescence and progresses to macroalbuminuria. Proteinuria is responsible for the progression to chronic kidney disease in some patients with SCD with glomerular filtration rate (GFR) decreased due to interactions between various processes involving the vascular, glomerular, tubular, and interstitial compartments of the kidney. Challenges: Renal complications are hardly identifiable in the early stages, as serum creatinine increases only in the final stages of SCN. Subnormal GFR and elevated serum creatinine levels develop only when there is significant proteinuria. Prevention and Treatment: The identification of biomarkers of early, non-invasive kidney injury, and their inclusion in clinical practice will contribute to the identification of the mechanisms involved in the development of renal syndromes, facilitating the development of more effective strategies in the prevention and treatment of SCD.</p>","PeriodicalId":10725,"journal":{"name":"Contributions to nephrology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contributions to nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000517703","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

Clinical Background: Renal involvement in sickle cell disease (SCD), called sickle cell nephropathy (SCN), includes several renal manifestations, such as renal acidification defect, distal nephron dysfunction, renal papillary necrosis, and proteinuria related to glomerular injury, leading to end-stage renal disease. Epidemiology: Many patients with SCD have a defect in urinary concentration, a problem caused by the destruction of the renal medulla that initiates in childhood. The presence of proteinuria in SCD is age-related and starts as microalbuminuria in adolescence and progresses to macroalbuminuria. Proteinuria is responsible for the progression to chronic kidney disease in some patients with SCD with glomerular filtration rate (GFR) decreased due to interactions between various processes involving the vascular, glomerular, tubular, and interstitial compartments of the kidney. Challenges: Renal complications are hardly identifiable in the early stages, as serum creatinine increases only in the final stages of SCN. Subnormal GFR and elevated serum creatinine levels develop only when there is significant proteinuria. Prevention and Treatment: The identification of biomarkers of early, non-invasive kidney injury, and their inclusion in clinical practice will contribute to the identification of the mechanisms involved in the development of renal syndromes, facilitating the development of more effective strategies in the prevention and treatment of SCD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
镰状细胞病与肾脏:病理生理学和新的生物标志物。
临床背景:镰状细胞病(SCD)累及肾脏,称为镰状细胞肾病(SCN),包括几种肾脏表现,如肾酸化缺损、远端肾单位功能障碍、肾乳头状坏死和肾小球损伤相关的蛋白尿,导致终末期肾脏疾病。流行病学:许多SCD患者都有尿浓度缺陷,这是由儿童期开始的肾髓质破坏引起的问题。SCD中蛋白尿的存在与年龄有关,从青春期的微量白蛋白尿开始,发展为大量白蛋白尿。蛋白尿是一些SCD患者进展为慢性肾脏疾病的原因,肾小球滤过率(GFR)由于涉及肾脏血管、肾小球、小管和间质室的各种过程之间的相互作用而降低。挑战:肾脏并发症在早期很难识别,因为血清肌酐只有在SCN的最后阶段才会升高。GFR亚正常和血清肌酐水平升高仅在有显著蛋白尿时发生。预防和治疗:识别早期、非侵入性肾损伤的生物标志物,并将其纳入临床实践,将有助于确定肾脏综合征发生的机制,促进制定更有效的预防和治疗SCD的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Contributions to nephrology
Contributions to nephrology 医学-泌尿学与肾脏学
CiteScore
1.50
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊介绍: The speed of developments in nephrology has been fueled by the promise that new findings may improve the care of patients suffering from renal disease. Participating in these rapid advances, this series has released an exceptional number of volumes that explore problems of immediate importance for clinical nephrology. Focus ranges from discussion of innovative treatment strategies to critical evaluations of investigative methodology. The value of regularly consolidating the newest findings and theories is enhanced through the inclusion of extensive bibliographies which make each volume a reference work deserving careful study.
期刊最新文献
Oxiris Membrane in Sepsis and Multiple Organ Failure. The Process of Adsorption and Cartridge Design. Introduction. Hemoperfusion in Trauma. Monitoring Treatment, Risks and Side Effects.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1